Log In
Print
BCIQ
Print
Print this Print this
 

Kadcyla, ado-trastuzumab emtansine, trastuzumab emtansine (T-DM1) (RG3502)

Also known as: trastuzumab-DM1

  Manage Alerts
Collapse Summary General Information
Company Genentech Inc.
DescriptionHumanized mAb against epidermal growth factor receptor 2 (EGFR2; HER2) linked to ImmunoGen's DM1 cytotoxic agent
Molecular Target Epidermal growth factor receptor 2 (EGFR2) (HER2) (ErbB2) (neu)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today